Scouting report · TNDM

John F. Sheridan

Tandem's President & CEO since March 2019, after six years as its COO

Born / age
(70)
Role
President & CEO; director
In the role
8 yr
Education
BS University of West Florida
Front Office rank
not ranked yet
TNDM
Tandem Diabetes Care, Inc.Medtech
Title
President & CEO; directorsrc
In role
since 2019-03 (8 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 24 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design67revenue, strategic, ebitda, relative tsr, time only · 97.3% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
97%Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
John F. Sheridan
Age
70src
Education
BS Chemistry, University of West Floridasrc

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
124,691 TNDM, 2026-03-16src
Traded, 12 months
bought $0, sold $0src
Last pay
$6.9m 2025src
Say-on-pay vote
97.3% forsrc
CEO pay ratio
73 : 1

What to weigh

Red flag 1

  • The CEO and CFO are domestic partners and the CFO reports to him. The board discloses this and has controls around it, but it concentrates the two key financial-reporting signatures in one householdsrc

Watch 5

  • Age 70, and the 2026 proxy does not mention CEO succession planning at all. He holds both the President and CEO titles; the COO (Kyrillos) joined in June 2024src
  • The Chief Commercial Officer, hired November 2023, was terminated without cause on 2026-05-11; the company said strategy and 2026 goals were unchangedsrc
  • The May 2026 equity grant reported on Form 4 was 191,103 time-vesting RSUs, with no PSU reported. In 2025 half the LTI was PSUs on EBITDA margin and relative TSRsrc
  • The 2025 bonus paid 87% of target although worldwide revenue ($1.015bn) missed the $1.054bn target and the revenue component earned 81%src
  • PSUs granted in 2023 on revenue CAGR and TSR vs the Russell 3000 were forfeited when neither target was metsrc

In their favour 1

  • Pay ratio 73:1 on $6.86m total 2025 pay, and base salary was held flat in 2023src

Pay

Salary and otherBonus, stock, options, incentive

  • $4.7m2023
  • $8.5m2024
  • $6.9m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2023$711k$0$3.7m$0$267k$11k$4.7msrc
2024$732k$0$7.1m$0$650k$11k$8.5msrc
2025$791k$0$5.4m$0$674k$26k$6.9msrc
Bonus pays on
Cash bonus, target 100% of salary: 80% worldwide revenue vs $1.054bn target (90% threshold, 200% cap), 10% four new product launches, 10% customer satisfaction KPI; paid 87% of target
Long-term award pays on
2025 LTI half PSUs (50% FY2027 adjusted EBITDA margin, 50% 2025-27 TSR percentile vs the Russell 3000) and half RSUs vesting over 36 months; May 2026 Form 4 grant was RSUs onlysrc
  • Pay at risk not on file
  • Pays on returns revenue, strategic, ebitda, relative tsr, time only
  • Shareholder vote 97.3% for
  • Pay vs profit company lost money

CEO pay ratio 73 : 1

Career

  1. 2019 – now
    Tandem Diabetes Caresrc
    President & CEO; director since June 2019
    Succeeded Kim Blickenstaff, who became Executive Chairman, effective 2019-03-01
  2. 2013 – 2019
    Tandem Diabetes Caresrc
    EVP & Chief Operating Officer
    Joined April 2013, before the November 2013 IPO
  3. 2012 – 2013
    Rapiscan Systems, Inc.src
    Chief Operating Officer (March 2012 to February 2013)
  4. 2004 – 2010
    Volcano Corporationsrc
    EVP, Research & Development and Operations (November 2004 to March 2010)
  5. 2002 – 2004
    CardioNet, Inc.src
    EVP, Operations (May 2002 to May 2004)
  6. 1998 – 2002
    Digirad Corporationsrc
    VP, Operations (March 1998 to May 2002)

Not located: 2010-03 to 2012-03 (between Volcano and Rapiscan) and 2004-05 to 2004-11 are not described in any filing searched; everything before 1998 not located

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family He and the CFO, Leigh Vosseller, are in a personal relationship and share a primary residence. She reports directly to him; the board knew before he became CEO in 2019, neither sets the other's pay, and the audit committee added internal controls. The proxy lists no other family relationshipssrc
  • Boards Director of Acutus Medical, Inc. from March 2021 to April 2025src
  • Legal Named defendant with the CFO in Lowe v. Tandem Diabetes Care (S.D. Cal., filed 2023-09-08) over 2022 sales trends and forecasts. Dismissed with leave to amend on 2024-04-29, then with prejudice on 2024-06-04; two derivative suits naming him were voluntarily dismissed in July 2024src
  • Legal A law firm posted a 2025 securities class action complaint over the t:slim X2 speaker correction (class period 2024-08-01 to 2025-08-07). This pass did not confirm the defendants or the status in a primary document; the Q2 2026 10-Q reports no proceeding with a probable or estimable material losssrc
  • Other The proxy reports no Item 401(f) legal proceedings for any director or executive officersrc

Sources13